Exploitable mechanisms for the blockade of androgenic action

Prostate

Volumn 45, Issue , 2000, Pages 43-51

  Griffiths, Keith ^a   Denis, Louis J ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Oncology Centre of Antwerp   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ENZYME INHIBITOR; ESTROGEN; FINASTERIDE; PROTEIN TYROSINE KINASE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; BICALUTAMIDE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ESTRADIOL; ESTROGEN RECEPTOR; FLUTAMIDE; FULVESTRANT; GEFITINIB; MEPARTRICIN; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; RALOXIFENE; TAMOXIFEN; UNCLASSIFIED DRUG; ZM 252868;

DRUG ANTAGONISM; DRUG COMBINATION; FORECASTING; HUMAN; INTRACELLULAR MEMBRANE; MALE; PHYSIOLOGY; PROSTATE TUMOR; REVIEW; SIGNAL TRANSDUCTION; CANCER HORMONE THERAPY; CONFERENCE PAPER; DOSE RESPONSE; DRUG MECHANISM; HORMONE INHIBITION; HORMONE RECEPTOR INTERACTION; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT;

ANDROGEN ANTAGONISTS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; ESTROGENS; FINASTERIDE; FORECASTING; HUMANS; INTRACELLULAR MEMBRANES; MALE; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 37649016275     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0045(2000)45:10+<43::AID-PROS9>3.0.CO;2-L     Document Type: Article

References (50)

1. Endocrine treatment of prostatic cancer
2. Goserelin acetate and flutamide versus bilateral orchiectomy: A phase III EORTC trial (30853)
3. Combined androgen blockade: The gold standard for metastatic prostate cancer
4. Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomised trials with 3283 deaths in 5710 patients
5. Possible relationship between dietary factors and pathogenesis of prostate cancer
6. Steroid 5alpha-reductase deficiency in man: An inherited form of male pseudohermaphroditism
7. Steroid hormone receptors: Interaction with deoxyribonucleic acid and transcription factors
8. New hormonal therapy in prostate cancer: Combined use of a pure anti-androgen and an LHRH agonist
9. Combination therapy with flutamide: The therapy of choice from early to advanced stages of prostate cancer
10. Steroids of adrenal origin metabolised by human prostate tissue, both in vivo and in vitro
11. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens
12. Mutant androgen receptor detected in an advanced stage of prostatic carcinoma is activated by adrenal androgens and progesterone
13. The antiandrogen withdrawal syndrome in relapsed prostate cancer
14. Androgen conjugates: Physiology and clinical significance
15. Prostatic epidermal growth factor receptors and their regulation by androgens
16. Endocrine factors in the initiation, diagnosis and treatment of prostatic cancer
17. Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer
18. Binding of epidermal growth factor by human normal, hypertrophic and carcinomatous prostate
19. Insulin like growth factor I: Action and receptor characterization in human prostate cancer cell lines
20. New targets for therapeutic attack
21. Therapeutic preparations containing quinazoline derivatives
22. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines
23. EGF receptor tyrosine kinase inhibitors as anti-cancer agents: Preclinical and early clinical profile of ZD1839
24. New EGF-R selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC3 and Du-145
25. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers
26. Oestrogen and growth factor crosstalk and endocrine insensitivity and acquired resistance in breast cancer
27. Endocrine response and failure in breast cancer: A role for the interplay of steroid and growth factor signalling pathways and therapeutic implications
28. Intermittent androgen suppression for prostate cancer: Rationale and clinical experience
29. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma
30. Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland
31. Estrogen replacement therapy and fractures in older women: The study of osteoporotic fractures research group
32. Postmenopausal oestrogen therapy and cardiovascular disease
33. Les oestrogenes et la prostate
34. Regulation of prostate growth
35. Cloning of a novel estrogen receptor expressed in rat prostate and ovary
36. ERβ: Identification and characterisation of a novel human estrogen receptor
37. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β
38. Nuclear receptor co-activators and corepressors
39. 70, for the androgen receptor in human prostate cells
40. Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a base for the cell- and promoter-specific action of these hormones
41. Ligand-dependent transcriptionally productive association of the amino- and carboxy-terminal region of a steroid hormone nuclear receptor
42. Hormonal therapy of prostate cancer: Limitations in the total androgen ablation concept
43. Prostate cancer and diet: Investigations, interventions and future considerations
44. Secondary endocrine treatment, treatment of hormone resistant disease and palliative care, psycho-social support and quality of life
45. Nuclear receptor/AP-1 interaction
46. Retinoic acid is a negative regulator of AP-1 responsive genes
47. Antagonism between retinoic acid receptors and AP-1: Implications for tumor promotion and inflammation
48. Vitamin D3 receptors: Structure and function in transcription
49. Characterisation of human estrogen receptor β